

References

1. **Abati AD, Kimmel M, and Rosen PP. (1996).** Breast. In: Ackerman's Surgical Pathology, 8th edition, edited by: Rosai J, Ackerman LV. London, Baltimore, Barcelona: Mosby; Vol. 2, Ch. 20, pp. 1565-660.
2. **Aisenberg AC. (1997).** High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer; 79:1203.
3. **Anderson TJ and Page DL. (1992).** Breast structure, biology and pathology. In: Oxford Textbook Of pathology, edited by: Isaacson P, Wright N, and McGee JO. Oxford, New York, Tokyo: Oxford University Press; Ch. 22(1), pp. 1643-81.
4. **Argy O, Hughes KS, and Roche GA. (2002).** Managing the Patients with a Breast Mass. In: Manual of Breast Diseases, 1st edition, edited by: Ismail Jatoui. London, New York, Philadelphia: Lippincott Williams & Wilkins; Ch. 6, pp. 135-48.
5. **Asa LS. (1999).** Advances in Pituitary Tumor Therapy. J. Clin. Endocrinol. Metab.; 28(1):13-43.
6. **Baker KS, Davey DD, and Stelling CB. (1994).** Ductal Abnormalities Detected with Galactography: Frequency of Adequate Excisional Biopsy. Am. J. Roentgenol.; 162:821-4.
7. **Baker JA, Kornguth PJ, and Soo MS. (1999).** Sonography of Solid Breast Lesions: Observer Variability of Lesion Description and Assessment. Am. J. Roentgenol.; 172:1621-5.

8. **Bartow SA. (1994).** The breast. In: Pathology textbook, 2nd edition, edited by: Rubin E, Farber JL. New York, Philadelphia, Toronto: Lippincott Williams & Wilkins Company; Ch. 19, pp. 973-91.

9. **Bassett LW and Hoyt AC. (2002).** Breast Imaging. In: Manual of Breast Diseases, 1st edition, edited by Ismail Jatoui. London, New York, Philadelphia: Lippincott Williams & Wilkins; Ch. 9, pp. 201-30.

10. **Bauer RL, Eckhert KH, and Nemoto T. (1998).** Ductal carcinoma in situ-associated nipple discharge: a clinical marker for locally extensive disease. Ann. Surg. Oncol.; 5:452-5.

11. **Bickell NA, Aufses AH Jr, and Chassin MR. (1998).** Engaging Clinicians in a QI Strategy for Early Stage Breast Cancer Treatment. Qual. Manag. Health Care; 6:63-8.

12. **Bijker N, Peterse JL, and Duchateau L. (2001).** Risk Factors for Recurrence and Metastasis after Breast Conserving Therapy for Dcis: Analysis of European Organization and Treatment of Breast Cancer Trial 10853. J. Clin. Oncol.; 19:2263-71.

13. **Biller BM. (1999).** Hyperprolactinemia. Int. J. Fertil. Womens Med.; 44:74-7.

14. **Blackwell RE and Grotting JC. (1996).** Screening and self-examination. In: Diagnosis and management of breast disease, 1st edition. London, New York, Paris: Blackwell Science Inc. Ch. 1, pp. 5-18.

15. **Bland KI and Romrell LJ. (1998).** Congenital and acquired disturbances of breast development and growth. In: The breast; Comprehensive Management of Benign and Malignant Diseases, 2nd edition, edited by: Bland KI and Copeland EM. Philadelphia, New York, London: W.B. Saunders; Ch. 6, pp. 214-32.
16. **Bland KI, Souba WW, and Copeland EM. (1999).** Surgery for Benign and Malignant Disease of the Breast: Indications and Techniques. In: Atlas of Surgical Oncology, 2nd edition. London, Philadelphia, Toronto: W.B. Saunders Company; Vol. 1, Ch. 8, pp. 181-230.
17. **Bland KI, vezeridis MP, and Copeland EM. (1999).** Breast. In: Principles of Surgery, 7th edition, edited by Schwartz SI, Tom Shires G, Spencer FC, Daly JM, Fischer JE, and Galloway AC. New York, St. Louis, San Francisco: McGraw Hill Companies; Vol. I, Ch. 14, pp. 533-99.
18. **Bland KI and Vezeridis MP. (2001).** Anatomy of the breast. In: Mastery of Surgery, 4th edition, edited by: Baker RJ and Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins. Vol. 2, Ch. 42, pp. 1565-73.
19. **Bland KI and Vezeridis MP. (2001).** Modified Radical Mastectomy with Early or Delayed Breast Reconstruction. In: Mastery of Surgery, 4th edition, edited by: Baker RJ, Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins; Vol 2. Ch. 47, pp. 1614-27.
20. **Bobo JK, Lee NC, and Thames SF. (2000).** Findings from 752081 clinical breast examinations reported to a national

screening program from 1995 through 1998. J. Natl. Cancer Inst. Monogr.; 92:971-6.

21. **Burns RB, Freund KM, and Ash AS. (1996).** As mammography use increase, are some providers omitting clinical breast examination?. Arch. Intern. Med.; 156:741-4.
22. **Cardenosa G and Eklund GW. (1991).** Benign papillary neoplasms of the breast: mammographic findings. Radiology; 181:751-5.
23. **Cardenosa G, Doubna C, and Eklund GW. (1994).** Ductography of Breast: Techniques and Findings. Am. J. Roentgenol.; 162:1081-7.
24. **Carty NJ, Mudan SS, and Ravichandran D. (1994).** Prospective study of outcome in women presenting with nipple discharge. Ann. R. Coll. Surg. Engl.; 76:387-9.
25. **Ceriani RL. (1974).** Proceedings: hormones and other factors controlling growth in the mammary gland: a review. J. Invest. Dermatol.; 63:93-108.
26. **Chang HR. (2001).** Local Treatment with Surgery. In: Cancer treatment, 5th edition, edited by: Haskell CM. Philadelphia, New York, London: W.B. Saunders Co.; Ch. 35, pp. 543-52.
27. **Chap LI, Barsky SH, and Bassett LW. (2001).** Natural History of Pretreatment Assessment. IN: Cancer Treatment, 5th edition, edited by: Haskell CM. New York, Boston, Paris: W.B. Saunders Company; Ch. 35, pp. 507-32.

28. **Chaudary M, Millis R, Davies G, and Hayward JL. (1982).** Nipple discharge: the diagnostic value of testing for occult blood. *Ann. Surg.*; 196:651-5.
29. **Chung SY, Lee KW, Park KS, and Bae SH. (1995).** Breast Tumors Associated with Nipple Discharge: Correlation of Findings on Galactography and Sonography. *Clin. Imaging*; 19:165-71.
30. **Connolly JL, Schnitt SJ, and Tavassoli FA. (1992).** The diagnosis of ductal proliferative breast lesions using standardized criteria. *Am. J. Surg. Pathol.*; 16:1133.
31. **Copeland M and Higgins T. (1960).** Significance of discharge from the nipple in nonpuerperal mammary conditions. *Ann. Surg.*; 151:638-48.
32. **Cormack DH. (2001).** Histology of the mammary glands. In: *Essential Histology*, 2nd edition. Philadelphia, Pennsylvania, Baltimore: Lippincott Williams & Wilkins Company; Ch. 17, pp. 408-9.
33. **Corriveau S and Jacobs JS. (1990).** Macromastia in adolescence. *Clin. Plast. Surg.*; 17:151.
34. **Cotran RS, Robbins SL, and Kumar V. (1995).** The female breast. In: *Pathologic Basis of Disease*, 5th edition, edited by: Cotran RS, Compton CC, Robbins SL. Philadelphia, New York, London: W.B. Saunders Company; Ch. 24, pp. 1089-125.
35. **Cowan DF and Herbert TA. (1989).** Involution of the breast in women aged 50 to 104 years: A histological study of 102 cases. *Surg. Pathol.*; 2:323-34.

36. **Curran RC and Crocker J. (2000).** Histopathology of the breast. In: Curran's Atlas of Histopathology, 4th edition. London, New York, Athens: Harvey Miller LTD; Ch.7, pp.101-31.
37. **Damjanov I. (1996).** Histopathology of the breast. In: Histopathology A Color Atlas and Textbook, 1st edition. New York, Philadelphia, London: Lippincott Williams & Wilkins; Ch. 14, pp.351-69.
38. **Danielsson R, Bone B, and Gad A. (1999).** Sensitivity and specificity of planar scintimammography with 99mTc-Sestamibi. Acta Radiol.; 40: 394-9.
39. **Dawes LG, Bowen L, and Venta LA. (1998).** Ductography for nipple discharge: No replacement for ductal excision. Surgery; 124:685-91.
40. **Devriedi K, Lemli L, and Craen M. (1995).** Growth Hormone Deficiency and Premature Thelarche in a Female Infant with Kabuki Makeup Syndrome. Horm. Res.; 43:303-6.
41. **Dickson RB and Lippman ME. (1992).** Molecular determinants of growth, angiogenesis, and metastases in breast cancer. Semin. Oncol.; 19:286.
42. **Dixon JM and Mansel RE. (1994).** Congenital problems and aberrations of normal breast development and involution. B. M. J.; 309:797.
43. **Dietz JR, and Crowe JF. (2002).** Nipple discharge. In: Manual of Breast Diseases, 1st edition, edited by Ismail Jatoui. London, New

York, Philadelphia: Lippincott Williams & Wilkins; Ch. 3, pp.55-76.

44. **Dietz JR, Crowe JP, Grundfest S, Arrigain S, and Kim JA. (2002).** Directed Duct Excision by Using Mammary Ductoscopy in Patients with Pathologic Nipple Discharge. *Surgery*; 132(4):582-8.
45. **Dominguez CF, Armendariz P, Perez-Cabanas I, Artieda C, Oteiza F, and Sanz MA. (1999).** Endoscopic Technique for the Localization of Intraductal Papillomas. *Br. J. Surg.*; 86:1470-1.
46. **Dooley WC. (2002).** Routine Operative Breast Endoscopy for Bloody Nipple Discharge. *Ann. Surg. Oncol.*; 9:920-3.
47. **Dunbar ME and Wysolmerski JJ. (1999).** Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development. *J. Mammary Gland Biol. Neoplasia*; 4:21-34.
48. **Dunn JM, Lucarotti E, and Wood SJ. (1995).** Exfoliative Cytology in the Diagnosis of Breast Disease. *Br. J. Surg.*; 82:789-91.
49. **Dunn NR, Freemantle SN, Pearce GL, and Mann RD. (1998).** Galactorrhoea with moclobemide [Letter]. *Lancet*; 351:802.
50. **Dupont WD, Parl FF, and Hartmann WH. (1993).** Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. *Cancer*; 71:1258.
51. **Dupont WD, Page DL, and Parl FF. (1994).** Long-term risk of breast cancer in women with fibroadenoma. *N. Engl. J. Med.*; 331:10.

52. **Eastman P. (1997).** NCI adopts new mammography screening guidelines for women. *J. Natl. Cancer Inst. Monogr.*; 89:538-9.
53. **Egberts AC, Meyboom RH, De Koning FH, Bakker A, and Leufkens HG. (1997).** Non-puerperal lactation associated with antidepressant drug use. *Br. J. Clin. Pharmacol.*; 44:277-81.
54. **Falkenberry SS. (2002).** Nipple discharge. *Obstet. Gynecol. Clin. North Am.*; 29:21-9.
55. **Faubion WA and Nader S. (1997).** Spinal cord surgery and galactorrhea: a case report. *Am. J. Obstet. Gynecol.*; 177:465-6.
56. **Fawcett DW and Jensch RP. (1997).** Mammary Glands, In: Bloom & Fawcett's Concise Histology, 2nd edition. New York, London, New Delhi: Chapman & Hall Company; Ch. 21, pp. 281-3.
57. **Feig SA. (2002).** Current Status of Screening Mammography. *Obst. Gynecol. Clin.*; 29(1):39-51.
58. **Feig SA and Hendrick RE. (1997).** Radiation risk from screening mammography of women aged 40-49 years. *J. Natl. Cancer Inst. Monogr.*; 22:119-24.
59. **Feig SA, Orel SG, and Dershaw DD. (2001).** Mammographic Technique, Equipment, and Quality Control. In: Grainger & Allison's Diagnostic Radiology, 4th edition, edited by: Zerhouni EA. London, Edinburgh, New York: Churchill Livingstone Inc.; Ch. 95, pp.2239-2275.
60. **Fetrow CW and Avila JR. (1999).** Professional's handbook of complementary & alternative medicines, 1st edition, Springhouse Pub. Co.; pp. 82-3, 248-9.

61. **Field LR, Wilson TE, and Strawderman M. (1998).** Mammographic screening in women more than 64 years old: a comparison of 1 and 2 years interval. *Am. J. Radiol.*; 170:961-5.
62. **Fiorica JV. (1994).** Nipple discharge. *Obestet. Gynecol. Clin. North Am.*; Ch 21:453-60.
63. **Fletcher SW. (1997).** Breast cancer screening among women in their forties: An overview of the issues. *J. Natl. Cancer Inst. Monogr.*; 22:5-9.
64. **Florio M, Manganaro T, and Polliciro A. (1999).** Surgical Approach to Nipple Discharge; a Ten-Year Experience. *J. Surg. Oncol.*; 71:235-8.
65. **Fortova L, Garber JE and Sadowsky NL. (1998).** Carcinoembryonic Antigen in Breast Nipple Aspirate Fluid. *Cancer Epidimiol. Biomarkers Prev.*; 7:177-81.
66. **Fung A, Rayter Z, and Fisher C. (1990).** Preoperative Cytology and Mammography in Patients with Single Duct Nipple Discharge Treated by Surgery. *Br. J. Surg.*; 77:1211-2.
67. **Gartner LP and Haitt GL. (2001).** Female reproductive system. In: *Color Textbook of Histology*, 2nd edition. Philadelphia, London, Toronto: W.B. Saunders Company; Ch. 20, pp. 483-6.
68. **Giuliano AE and Haigh PI. (2001).** Sentinel lymph node biopsy in breast cancer. In: *Mastery of Surgery*, 4th edition, edited by: Baker RJ, Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins; Vol. 2. Ch. 45, pp. 1597-600.

69. **Goodson WH and King EB. (1998).** Discharges and secretions of the nipple. In: The breast; Comprehensive Management of Benign and Malignant Diseases, 2nd edition, edited by: Bland KI and Copeland EM. Philadelphia, New York, London: W.B. Saunders; pp.51-74.
70. **Gulay H, Bora S, and Kilicturgay S. (1994).** Management of nipple discharge. J. Am. Coll. Surg.; 178:471-4.
71. **Guven K and Kelestimur F. (1995).** Hyperprolactinemia and galactorrhea with standard-dose famotidine therapy [Letter]. Ann. Pharmacother; 29:788.
72. **Haagenses CD. (1986).** Physiology of the breast. In: Diseases of the Breast, 3rd edition. New York, London, Philadelphia: W.B. Saunders; Ch.2, pp.18-29.
73. **Harms SE. (1998).** Breast magnetic resonance imaging. Radiology; 204:104-20.
74. **Harris JR and Marrow M. (1996).** Local Management of Invasive Breast Cancer. In: Diseases of the Breast, 1st edition. Philadelphia, New York, London: Lippincott Williams & Wilkins Company; Ch. 29, pp. 487.
75. **Harris J, Marrow M, and Norton L. (1997).** Malignant tumors of the breast In: Cancer: Principles and practice of oncology, 5th edition, edited by: Vincent T. Devita VT, Rosenberg SA, and Hellman S. Philadelphia, New York, London: Lippincott Williams & Wilkins; Ch. 36(2), pp. 1557-615.

76. **Harris JR, Lippman ME, Morrow M, and Osborne CK. (2000).** Breast anatomy and development. In: Diseases of the Breast, 2nd edition, New York, Philadelphia, Boston: Lippincott Williams & Wilkins. Ch. 1, pp. 1-13.
77. **Harris JR, Lippman ME, and Morrow M. (2000).** Techniques of surgery. In: Diseases of the Breast, 2nd edition, edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia, New York, London: Lippincott Williams & Wilkins Company; Ch. 35, pp. 577-88.
78. **Harris JR. (2000).** Staging of breast cancer. In: Diseases of the Breast, 2nd edition, edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia, New York, London: Lippincott Williams & Wilkins Company; Ch. 28, pp. 403-6.
79. **Helzlsouer KJ and Couzi R. (1995).** Hormones and breast cancer. Cancer; 76:2059.
80. **Henneman PL. (2002).** Guaiac test. In: Rosen's Emergency Medicine; Concepts and Clinical Practice, 5th edition, edited by: Marx JA, Hockberger RS, and Walls RM. St. Louis, London, Sydney: Mosby; pp. 196.
81. **Hussain S and Lui DM. (1997).** Ultrasound Guided Percutaneous Galactography. Eur. J. Radiol.; 24:163-5.
82. **Huston SW, Cowen PN, and bird CC. (1985).** Morphologic studies of age related changes in normal human breast and their significance in the evolution of mammary cancer. J. Clin. Path.; 38:281-7.

83. **Huynh PT, Jarolimek AM, and Daye S. (1998).** The false-negative mammogram. *Radiographics*; 18:137-54.
84. **Iglehart JD and Kaelin CM. (2001).** Diseases of the breast. In: *Sabiston Textbook of Surgery*, 16th edition, edited by: Townsend CM, Beauchamp RD, Evers BM, and Mattox KL. Philadelphia, London, New York: W.B. Saunders Company; Ch. 30, pp. 555-90.
85. **Imayama IS, Mori M, and Ueo H. (1996).** Presence of Elevated Carcinoembryonic Antigen on Absorbent Disks Applied to Nipple Area of Breast Cancer Patients. *Cancer*; 78:12229-34.
86. **Ito Y, Tamaki Y, and Nakano Y. (1997).** Non-palpable Breast Cancer with Nipple Discharge: How Should It Be Treated? *Anticancer Res.*; 17:791-4.
87. **Jackson VP, Dines KA, and Bassett LW. (1991).** Diagnostic Importance of the Radiographic Density of Non-Calcified Breast Masses: Analysis of 91 Lesions. *Amr. J. Radiol.*; 157:25-8.
88. **Jardines L. (1996).** Management of Nipple Discharge. *Am. Surg.*; 62:199-22.
89. **Jatoi I. (2002).** Principles of Breast Cancer Screening In: *Manual of Breast Diseases*, 1st edition. London, New York, Philadelphia: Lippincott Williams & Wilkins; Ch. 8, pp. 177-200.
90. **Kaplowitz PB and Oberfield SE. (1999).** Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. *Pediatrics*; 104:936-41.

91. **Katsuren E, Ishikawa S, Honda K, and Saito T. (1997).** Galactorrhoea and amenorrhoea due to an intradural neurinoma originating from a thoracic intercostal nerve radicle. Clin. Endocrinol.; 46:631-6.
92. **Katznelson L and Klibanski A. (1999).** Hyperprolactinemia: physiology and clinical approach. In: Pituitary disorders: comprehensive management, 1st edition, edited by: Krisht AF and Tindall GT. Baltimore, London, Athens: Lippincott Williams & Wilkins; pp. 189-98.
93. **Kawamoto M. (1994).** Breast Cancer Diagnosis by Lactate Dehydrogenase Isoenzymes in Nipple Discharge. Cancer; 73:1836-41.
94. **Keller-Wood M and Bland KI. (1991).** Breast physiology in normal, lactating, and diseased states. In: The breast; Comprehensive Management of Benign and Malignant Diseases, 1st edition, edited by: Bland KI and Copeland EM. Philadelphia, New York, London: W.B. Saunders; Ch. 3, pp. 36-45.
95. **Kelly OR, Junqueira LC, and Carneiro J. (1998).** Mammary glands. In: Basic Histology, 9th edition. Toronto, New Delhi, London: Appleton & Lange Company; Ch. 23, pp. 442-4.
96. **Kenney PJ. (1996).** Magnetic Resonance Imaging of the Female Breast. In: Diagnosis and management of breast disease, 1st edition, edited by: Blackwell RE and Grotting JC. London, New York, Paris: Blackwell Science Inc. Ch. 8, pp.193-210.

97. **Kerlikowske K, Grady D, and Rubin SM. (1995).** Efficacy of screening mammography: a meta-analysis. JAMA; 273:149-54.
98. **Kerlikowske K and Barclay J. (1997).** Outcomes of modern screening mammography. J. Natl. Cancer Inst. Monogr.; 22:105-11.
99. **King TA, Carter KM, Bolton JS, and Fuhrman GM. (2000).** A simple approach to nipple discharge. Am. Surg.; 66(10):960-5.
100. **Kinne DW, Petrek JA, and Osborne MP. (1989).** Breast Carcinoma In-situ. Arch. Surg.; 121:33.
101. **Klein KO and Brown-Dawson J. (1999).** Estrogen levels in girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive recombinant cell bioassay. J. Pediatr.; 134:190-2.
102. **Klibanski A and Zervas NT. (1991).** Diagnosis and management of hormone-secreting pituitary adenomas. N. Engl. J. Med.; 324:822-31.
103. **Kohlmeier L and Mendez M. (1997).** Controversies surrounding diet and breast cancer. Proc. Nutr. Soc.; 56:369.
104. **Kopans DB. (2000).** Imaging Analysis of Breast Lesions. In: Diseases of the Breast, 2nd edition, edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia, New York, London: Lippincott Williams & Wilkins Company; Ch.12, pp. 123-47.
105. **Kuhl CK, Bieling HB, and Gieseke J. (1997).** Healthy Premenopausal Breast Parenchyma in Dynamic Contrast-

Enhanced MR Imaging of the Breast: Normal Contrast Medium Enhancement and Cyclical Phase Dependency. *Radiology*; 203:137-44.

106. **Larsen WJ. (1993).** Development of the integumentary system; the mammary glands. In: *Human Embryology*, 1st edition. London, New York, Singapore: Churchill Livingstone Inc.; Ch. 14, pp. 28-9.
107. **Lawson G. (2002).** Anatomy and physiology of the breast. In: *Manual of Breast Diseases*, 1st edition, edited by Ismail Jatoi. London, New York, Philadelphia: Lippincott Williams & Wilkins; Ch. 1, pp. 1-24.
108. **Lee CH. (2002).** Screening mammography: Proven benefit, continued controversy. *Radiol. Clin. North Am.*; 40(3):85-90.
109. **Lester SC and Cotran RS. (1999).** The breast. In: *Robbins Pathologic Basis of Disease*, 6th edition, edited by: Cotran RS, Kumar V, Collins T, Robbins SL, and Schmitt B. Philadelphia, London, New York: W.B. Saunders Company; Ch.25, pp.1093-119.
110. **Liljegen G and Holmberg L. (1997).** Arm Morbidity after Sector Resection and Axillary Dissection with or without Postoperative Radiotherapy in Breast Cancer Stage I: Results from a Randomised Trial. *Eur. J. Cancer*; 33:193.
111. **Liu Y, Wang JL, and Chang H. (2000).** Breast Cancer Diagnosis with Nipple Fluid Basic Fibroblast Growth Factor (letter). *Lancet*; 365:567.

112. **London SJ. (1992).** A prospective study of benign breast disease and the risk of breast cancer. JAMA; 267:941.
113. **Longacre TA and Barlow SA. (1986).** A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am. J. Surg. Pathol.; 10:382-93.
114. **Magnant CM. (1998).** Management of primary carcinoma and the axilla. In: Surgery of the breast, principles and art, 1st edition, edited by: Spear SL, Little JW, Lippman ME, and Wood WC. Baltimore, London, Philadelphia: Lippincott Williams & Wilkins; Ch. 8, pp. 111-35.
115. **Malone KE. (1998).** BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA; 279:922.
116. **Marchant DJ. (2002).** Benign Breast Disease. Obst. Gyn.Clin. North Am.; 29(1):139-61.
117. **Marshall LM. (1997).** Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol. Biomarkers Prev.; 6:297.
118. **McGonigle KF and Huggins GR. (1991).** Oral contraceptives and breast disease. Fertil. Steril.; 56:799.
119. **McManus MJ and Welch CW. (1984).** The effect of estrogen, progesterone, thyroxine and human placental lactogen on DNA

synthesis of human breast ductal epithelium maintained in athymic nude mice. *Cancer*; 54:1920-7.

120. **McMinn RM. (1990).** Anatomy of the breast. In: *Last's Anatomy; Regional and Applied*, 8th edition. Edinburgh, London, New York: Longman Group UK Ltd.; Ch. 2, pp. 70-2.
121. **McVay CB. (1984).** Breast anatomy. In: *Surgical Anatomy*, 6th edition. Philadelphia, London, New York: W.B. Saunders Company. Vol. I, Ch. 2, pp. 352-65.
122. **Mendenhall NP. (2001).** Breast Conserving Therapy for Early Stage Breast Cancer. *Haematol. Clin. N. Amr.*; 15(2): 242-9.
123. **Mills JL, Stolley PD, and Davies J. (1981).** Premature thelarche: natural history and etiologic investigation. *Am. J. Dis. Child.*; 135:743-5.
124. **Mittra I, Baun M, and Thornton H. (2000).** Is clinical breast examination an acceptable alternative to mammographic screening?. *Br. Med. J.*; 321:1071-3.
125. **Molitch ME. (1999).** Medical Treatment of Prolactinomas. *Endocrinol. Metab. Clin. North Am.*; 28:143-69.
126. **Molitch ME. (1999).** Management of Prolactinomas during Pregnancy. *J. Reprod. Med.*; 44:1121-6.
127. **Montvale NJ. (2000).** Physicians' desk reference: companion guide, 54th edition. Philadelphia, London, New York: Medical Economics Company; pp. 1293, 1315, 1337.

128. **Morange I, Barlier A, and Pellegrini I. (1996).** Prolactinomas Resistant To Bromocriptine: Long-Term Efficacy of Quinagolide and Outcome of Pregnancy. *Eur. J. Endocrinol.*; 135:413.
129. **Morrow M. (2000).** The evaluation of common breast problems. *Am. Fam. Physician* ; 61(8):2371-8, 2385.
130. **Morrow M. (2001).** Segmental mastectomy and axillary dissection. In: *Mastery of Surgery*, 4th edition, edited by: Baker RJ, Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins; Vol. 2. Ch. 44, pp. 1588-96.
131. **Neifert M, DeMarzo S, and Seacat J. (1990).** The influence of breast surgery, breast appearance, and pregnancy-induced breast changes on lactation sufficiency as measured by infant weight gain. *Birth*; 17:31.
132. **Neifert MR. (1999).** Clinical aspects of lactation: promoting breast-feeding success. *Clin. Perinatol.*; 26:281.
133. **Neinstein LS. (1999).** Breast disease in adolescents and young women. *Pediatr. Clin. North Am.*; 46:607-629.
134. **Neinstein LS. (1999).** *Adolescent Health Care: A Practical Guide*, 3rd edition. New York, Boston, Baltimore: Lippincott Williams & Wilkins. pp. 18-19.
135. **Neville MC. (2001).** Anatomy and physiology of lactation. *Ped. Clin. North Am.*; 48(1):13-34.
136. **Noguchi S. (1994).** Clonal analysis of solitary intraductal papilloma of the breast by means of polymerase chain reaction. *Am. J. Pathol.*; 144:1320.

137. **Nystrome L, Rutqvist LE, and Wall S. (1993).** Breast cancer screening with mammography: Overview of Swedish randomized trial. *Lancet*; 341:973-8.
138. **Obedian E and Haffty BG. (2000).** Breast-conserving therapy in breast cancer patients presenting with nipple discharge. *Int. J. Radiat. Oncol. Biol. Phys.*; 47:137-42.
139. **Omar S, Contesso G, and Khaled H. (2001).** Breast imaging. In: *Breast Cancer*, 4th edition. Cairo: Association Medicale Franco-Egyptienne; Ch. 6, pp. 57-71.
140. **Omar S, Contesso G, and Khaled H. (2001).** Pathology of the breast. In: *Breast Cancer*, 4th edition. Cairo: Association Medicale franco Egyptienne; Ch. 7, pp. 72-85.
141. **Orel SG. (2000).** MR Imaging of the Breast. *Radiol. Clin. N. Am.*; 38(4):899-913.
142. **Osborne MP. (1996).** Breast development and anatomy. In: *Diseases of the Breast*, 1st edition, edited by: Harris JR, Lippman ME, and Morrow M. New York, Philadelphia: Lippincott-Raven Publishers; Ch.1, pp. 1-14.
143. **Osin PP, Anbazhagan R, and Bartkova J. (1998).** Breast development gives insights into breast disease. *Histopathology*; 33:275-83.
144. **Osteen RT. (2002).** Unusual presentations of breast cancer. In: *Manual of Breast Diseases*, 1st edition, edited by Ismail Jatoi. London, New York, Philadelphia: Lippincott Williams & Wilkins; Ch. 16: 353-63.

145. **O'Grady LF, Lindfors KK, Rippon MP, and Howell LP. (2000).** A practical approach to breast disease, 2nd edition. New York, Philadelphia, Boston: Little, Brown and Company. Pp. 131-39.
146. **Pasquino AM, Pucarelli I, and Passeri F. (1995).** Progression of premature thelarche to central precocious puberty. J. Pediatr.; 126:11-14.
147. **Pass HA. (2001).** Benign and malignant diseases of the breast. In: Surgery; Basic Science and Clinical Evidence, 1st edition, edited by: Norton JA, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, Pass HI, and Thompson RW. New York, Berlin, Heidelberg: Springer Inc.; Ch. 78, pp. 1699-733.
148. **Petrakis NL. (1986).** Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res. Treat.; 8:7-19.
149. **Petrakis NL, Lee RE, and Miike R. (1988).** Coloration of breast fluid related to concentration of cholesterol, cholesterol epoxides, estrogens and lipid peroxides. Am. J. Clin. Pathol.; 89:117-20.
150. **Radford DM and Zehnbaauer BA. (1996).** Inherited breast cancer. Surg. Clin. North. Am.; 76:205.
151. **Reyniak JV. (1979).** Endocrine physiology of the breast. J. Reprod. Mod.; 22:303-9.
152. **Reynolds HE. (1999).** Advances in Breast Imaging. Haemat. Oncol. Clin. N. Amr.; 13(2):333-48.

153. **Ries L, Eisner M, and Kosary C. (2000).** SEER cancer statistics review 1973-1997 Bethesda, MD. Natl. Cancer Inst. Monogr.; 92:1231.
154. **Robinson GW, Karpf AB, and Kratochwil K. (1999).** Regulation of mammary gland development by tissue interaction. J. Mammary Gland Biol. Neoplasia; 4:9-19.
155. **Rongione AJ, Evans BD, and Kling KM. (1996).** Ductography is a Useful Technique in the Evaluation of Abnormal Nipple Discharge. Am. Surg.; 62:785-8.
156. **Rosen PP and Oberman HA. (1993).** Tumors of the Mammary Gland. In: Atlas of Tumor Pathology, 3rd edition. Washington, Boston, New York: Amer. Registry of Pathology; pp. 133-96.
157. **Rosenberg CL. (1996).** Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J. Clin. Invest.; 98:1095.
158. **Rosenberg CL. (1997).** Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum. Pathol.; 28:214.
159. **Rosenfeld J. and Pena KS. (2001).** Evaluation and treatment of galactorrhea. Am. Fam. Physician; 61:1763-70, 1775.
160. **Rosi J. (1996).** Breast; In: Ackerman's Surgical Pathology, 8th edition, edited by: Rosai J, Ackerman LV. London, Baltimore, Barcelona: Mosby; Vol. 2, Ch. 20, pp. 1565-660.
161. **Sainsbury R. (2001).** Treatment of early stage of breast cancer. In: Breast Surgery. 2nd edition, edited by:

Farndon JR. St. Louis, Sydney, Toronto: WB-Saunders Co, Ch. 3, pp. 67-92.

162. **Sakorafas GH. (2001).** Nipple discharge: current diagnostic and therapeutic approaches. *Cancer Treat. Rev.*; 27(5):275-82.
163. **Sanfilippo JS. (1999).** Implications of not-treating hyperprolactinemia. *J. Reprod. Med.*; 44:1111-5.
164. **Sardanelli F, Imperiale A, and Zandrino F. (1997).** Breast Intraductal Masses: Ultrasound Guided Fine Needle Aspiration After Galactography. *Radiology*; 204:143-8.
165. **Sauter ER, Daly M, and Linahan K. (1996).** Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. *Cancer Epidemiol. Biomarkers Prev.*; 5:967-70.
166. **Schmidt RA. (1994).** Stereotactic Breast Biopsy. *Can. Cancer J. Clin.*; 44:172-91.
167. **Schnitt SJ, Jimi A, and Kojiro M. (1993).** The increasing prevalence of benign proliferative breast lesions in Japanese women. *Cancer*; 71:2527.
168. **Schnitt SJ and Guidi AJ. (2000).** Pathology and Biological Markers of invasive Breast Cancer. In: *Diseases of the Breast*, 2nd edition, edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia, London, New York: Lippincott Williams & Wilkins Company; Ch. 30, pp. 425.
169. **Schwartz GF and Terribile D. (2002).** The treatment of DCIS of the breast. *Obst. Gyn. Clin. North Am.*; 29(1):162-70.

170. **Segatore M and Edge DS. (1993).** Assessment and management of galactorrhea. *Nurse Pract.*; 18:35-6, 38, 43-4.
171. **Shumate CR. (1996).** Surgical Evaluation and Treatment of Breast Cancer. In: *Diagnosis and management of breast disease*, 1st edition, edited by: Blackwell RE and Grotting JC. London, New York, Paris: Blackwell Science Inc. Ch. 9:211-24.
172. **Sharkey FE, Allerd DC, and Valente PT. (1996).** Breast. In: *Anderson's Pathology*, 10th edition, edited by: Damjanov I, Linder J. Baltimore, St. Louis, Boston: Mosby; Ch.70, pp. 2354-85.
173. **Shaughnessy EA. (2001).** Management of Minimally Invasive and In-situ Carcinoma of the Breast. In: *Mastery of Surgery*, 4th edition, edited by: Baker RJ, Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins; Vol. 2. Ch. 46, pp. 1601-13.
174. **Shermak MA. (2002).** Congenital and developmental abnormalities of the breast. In: *Manual of Breast Diseases*, 1st edition, edited by Ismail Jatoi. London, New York, Philadelphia: Lippincott Williams & Wilkins. Ch. 2, pp. 25-53.
175. **Sickles EA. (1991).** The Subtle and Atypical Mammographic Features of Invasive Lobular Carcinoma. *Radiology*; 178:25-6.
176. **Sirovich BE and Sox HC. (1999).** Breast cancer screening. *Surg. Clin. North Am.*; 79(5):961-90.
177. **Silverstein MJ, Cohlán BF, and Gierson ED. (1992).** Breast; In *Anderson's Pathology*, 9th edition, edited by: Anderson WD, John

- Kissnane J. London, Madrid, Mexico City: Mosby; Ch. 68, pp. 1823-65.
178. **Singleary E, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutier RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, and Greene FL. (2002).** Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. *J. Clin. Oncol.*; 20(17):3628-36.
 179. **Sinnatamby CS. (2001).** Anatomy of the Breast. In: *Last's Anatomy; Regional and Applied*, 10th edition. Edinburgh, Philadelphia, New York: Churchill Livingstone Inc.; Ch. 2, pp. 35-105.
 180. **Skandalakis JE, Skandalakis PN, and Skandalakis LJ. (2000).** Anatomy of the Breast. In: *Surgical Anatomy and Technique*, 2nd edition. New York, Berlin, Paris: Springer Inc.; Ch 3, pp. 99-123.
 181. **Smith DN. (2001).** Breast Ultrasound. *Radiol. Clin. N. Am.*; 39(3):719-32.
 182. **Smith RA and D'Orsi CJ. (2000).** Screening for breast cancer. In: *Diseases of the Breast*, 2nd edition, edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia, New York, London: Lippincott Williams & Wilkins Company; Ch. 11, pp. 101-22.
 183. **Smith WL, Erenberg A, and Nowak A. (1988).** Imaging evaluation of the human nipple during breastfeeding. *Am. J. Dis. Child.*; 142:76.

184. **Srivastava A, Griwan MS, and Samaiyar SS. (1995).** A Safe Technique of Major Mammary Duct Excision. *J. R. Coll. Surg. Edinb.*; 40:35-7.
185. **Stevens A and Lowe J. (2001).** Skin and Breast. In: *Human Histology*, 2nd edition. London, Baltimore, Barcelona: Mosby; Ch. 18, pp. 370-5.
186. **Tabar L, Vitak B, and Chen H. (2000).** The Swedish two-county trial twenty years later. *Radiol. Clin. North Am.*; 38:625-52.
187. **Tenore A, Franzese A, and Quattrin T. (1991).** Prognostic signs in the evolution of premature thelarche by discriminant analysis. *J. Endocrinol. Invest.*; 14:375-81.
188. **Toniolo PG. (1995).** A prospective study of endogenous estrogens and breast cancer in postmenopausal women. *J. Natl. Cancer Inst.*; 87:190.
189. **Turton DB and Shakir KM. (1995).** Galactorrhea caused by esophagitis. *Am. J. Obstet. Gynecol.*; 173:1629-30.
190. **Van Winter JT, Noller KL, and Zimmerman D. (1990).** Natural history of premature thelarche in Olmsted County, Minnesota, 1940-1984. *J. Pediatr.*; 16:278-80.
191. **Van Zee KJ, Perez GO, and Minnard E. (1998).** Preoperative Galactography Increases the Diagnostic Yield of Major Duct Excision for Nipple Discharge. *Cancer*; 82:1874-80.
192. **Veldhuis JD, Evans WS, and Johnson MD. (1989).** Mechanisms that subserve estradiol's induction of increased prolactin

concentrations: Evidence of amplitude modulation of spontaneous prolactin secretory bursts. *Am. J. Obstet. Gynecol.*; 161:1149.

193. **Verrotii A, Ferrari M, and Morgese G. (1996).** Premature thelarche: a long term follow-up. *Gynecol. Endocrinol.*; 10:241-7.
194. **Vogel PM, Georgiade NG, and Fetter BF. (1981).** The correlation of histological changes in the human breast with the menstrual cycle. *Am. J. Pathol.*; 104:23-34.
195. **Volta C, Bernasconi S, and Cistemino M. (1998).** Isolated premature thelarche variant: clinical and auxological follow-up of 119 girls. *J. Endocrinol. Invest.*; 21:180-3.
196. **Wahl RL. (1998).** Overview of the current status of PET in breast cancer imaging. *J. Nucl. Med.*; 42:1-7.
197. **Warren R, Hayes C, and Group SA. (2000).** Localization of breast lesions shown only on MRI: a review for UK study of MRI screening for breast cancer. *Br. J. Radiol.*; 73:123-32.
198. **Warren R. (2001).** Screening women at high risk of breast cancer on the bases of evidence. *Eur. J. Radiol.*; 39:50-9.
199. **Winchester DP and Lesnefsky MH. (2001).** Diagnostic Approach to Breast Abnormalities. In: *Mastery of Surgery*, 4th edition, edited by: Baker RJ, Fischer JE. London, New York, Philadelphia: Lippincott Williams & Wilkins; Vol. 2; Ch. 43, pp. 1574-87.
200. **Windgassen K, Wesselmann U, and Schulze Monking H. (1996).** Galactorrhea and hyperprolactinemia in schizophrenic

patients on neuroleptics: frequency and etiology. Neuropsychology; 33:142-6.

201. **Yant J, Buluwela L, and Niranjan B. (1998).** In vivo effects of hepatocyte growth factor/scatter factor on mouse mammary gland development. Exp. Cell Res.; 241:476-81.
202. **Yashimoto M, Kasumi F, and Lawse T. (1997).** Magnetic Resonance Galactography for a Patient with Nipple Discharge. Breast cancer Res. Treat.; 42:87-90.
203. **Yazigi RA, Quintero CH, and Salameh WA. (1997).** Prolactin disorders. Fertil. Steril; 67:215-25.
204. **Ziegler J. (1997).** An unlikely link? Researchers probe viral role in breast cancer [news]. J. Natl. Cancer Inst.; 89:608.